XTX Topco Ltd Takes $582,000 Position in AngioDynamics, Inc. (NASDAQ:ANGO)

XTX Topco Ltd bought a new stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 74,816 shares of the medical instruments supplier's stock, valued at approximately $582,000. XTX Topco Ltd owned approximately 0.18% of AngioDynamics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Quarry LP increased its stake in shares of AngioDynamics by 75.1% in the 2nd quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier's stock worth $37,000 after acquiring an additional 2,594 shares during the last quarter. CWM LLC increased its stake in shares of AngioDynamics by 981.3% in the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier's stock worth $76,000 after acquiring an additional 8,832 shares during the last quarter. Mackenzie Financial Corp acquired a new stake in shares of AngioDynamics in the 2nd quarter worth $80,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of AngioDynamics in the 3rd quarter worth $86,000. Finally, AE Wealth Management LLC acquired a new stake in shares of AngioDynamics in the 2nd quarter worth $87,000. Hedge funds and other institutional investors own 89.43% of the company's stock.

AngioDynamics Trading Down 2.0 %

AngioDynamics stock traded down $0.18 during midday trading on Friday, reaching $9.00. 475,237 shares of the stock traded hands, compared to its average volume of 532,501. The company has a 50-day simple moving average of $6.97 and a two-hundred day simple moving average of $6.93. AngioDynamics, Inc. has a 12-month low of $5.26 and a 12-month high of $9.42. The firm has a market cap of $365.67 million, a PE ratio of -1.48 and a beta of 0.68.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. The business had revenue of $67.50 million for the quarter, compared to analyst estimates of $67.93 million. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The business's quarterly revenue was down 14.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.12) EPS. Equities research analysts anticipate that AngioDynamics, Inc. will post -0.41 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $14.00 target price on shares of AngioDynamics in a research note on Tuesday. Canaccord Genuity Group cut their price objective on AngioDynamics from $13.00 to $12.00 and set a "buy" rating for the company in a research report on Friday, October 4th.

Insider Activity

In other AngioDynamics news, CEO James C. Clemmer purchased 20,000 shares of the firm's stock in a transaction that occurred on Monday, October 7th. The shares were purchased at an average cost of $6.03 per share, for a total transaction of $120,600.00. Following the completion of the purchase, the chief executive officer now directly owns 681,582 shares in the company, valued at $4,109,939.46. This represents a 3.02 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders have purchased 22,568 shares of company stock valued at $135,847. Company insiders own 5.40% of the company's stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.